Intra-Cellular Therapies, Inc. Quarterly Debt-to-equity in % from Q3 2015 to Q2 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Intra-Cellular Therapies, Inc. quarterly Debt-to-equity history and growth rate from Q3 2015 to Q2 2024.
  • Intra-Cellular Therapies, Inc. Debt-to-equity for the quarter ending June 30, 2024 was 19.7 %, a 27.8% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2024 19.7 +4.28 +27.8% Jun 30, 2024
Q1 2024 21.2 +7.07 +50.1% Mar 31, 2024
Q4 2023 18.8 +6.11 +48.4% Dec 31, 2023
Q3 2023 16.7 +3.97 +31.1% Sep 30, 2023
Q2 2023 15.4 +2.66 +20.9% Jun 30, 2023
Q1 2023 14.1 +1.21 +9.39% Mar 31, 2023
Q4 2022 12.6 -0.73 -5.46% Dec 31, 2022
Q3 2022 12.8 +1.28 +11.1% Sep 30, 2022
Q2 2022 12.7 +2.58 +25.4% Jun 30, 2022
Q1 2022 12.9 +2.46 +23.6% Mar 31, 2022
Q4 2021 13.4 +2.59 +24% Dec 31, 2021
Q3 2021 11.5 -1.95 -14.5% Sep 30, 2021
Q2 2021 10.1 -7.88 -43.7% Jun 30, 2021
Q1 2021 10.4 -8.83 -45.8% Mar 31, 2021
Q4 2020 10.8 -11.7 -52% Dec 31, 2020
Q3 2020 13.4 -4.97 -27% Sep 30, 2020
Q2 2020 18 +3.32 +22.6% Jun 30, 2020
Q1 2020 19.3 +8.35 +76.4% Mar 31, 2020
Q4 2019 22.5 +14.7 +189% Dec 31, 2019
Q3 2019 18.4 +12.7 +220% Sep 30, 2019
Q2 2019 14.7 +9.92 +207% Jun 30, 2019
Q1 2019 10.9 +6.75 +162% Mar 31, 2019
Q4 2018 7.78 +3.63 +87.4% Dec 31, 2018
Q3 2018 5.74 +1.62 +39.2% Sep 30, 2018
Q2 2018 4.78 -7.88 -62.2% Jun 30, 2018
Q1 2018 4.17 -8.54 -67.2% Mar 31, 2018
Q4 2017 4.16 -7.29 -63.7% Dec 31, 2017
Q3 2017 4.13 -6.34 -60.6% Sep 30, 2017
Q2 2017 12.7 +9.88 +355% Jun 30, 2017
Q1 2017 12.7 +10.3 +421% Mar 31, 2017
Q4 2016 11.4 +8.33 +268% Dec 31, 2016
Q3 2016 10.5 +6.04 +136% Sep 30, 2016
Q2 2016 2.78 Jun 30, 2016
Q1 2016 2.44 Mar 31, 2016
Q4 2015 3.11 Dec 31, 2015
Q3 2015 4.43 Sep 30, 2015
* An asterisk sign (*) next to the value indicates that the value is likely invalid.